AI Article Synopsis
- Detecting polymorphic DNA sequence variants can lead to better healthcare, but it raises ethical concerns about confidentiality.
- Some polymorphisms only cause small changes in disease risk and are hard to measure, making them less useful for health improvements.
- Biobank initiatives are being created to identify significant variants, but they also emphasize the importance of maintaining confidentiality and addressing ethical issues.
Article Abstract
The ability to detect polymorphic DNA sequence variants poses both opportunities for improved healthcare and concerns about the ethical challenges and confidentiality issues involved. Many polymorphisms confer only minor variability in disease susceptibility, which are difficult to detect and quantify, and therefore of minor value for improving healthcare. Important exceptions are high penetrance but uncommon disease susceptibility mutations, and those altering drug metabolism, knowledge of which should influence medical management. The development of Biobank initiatives to promote the detection and evaluation of important polymorphic variants highlights the need to ensure appropriate confidentiality guarantees and continuing debate about the ethical issues.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4952453 | PMC |
| http://dx.doi.org/10.7861/clinmedicine.3-3-260 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!